GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Beneish M-Score

argenx SE (argenx SE) Beneish M-Score : -1.02 (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.02 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for argenx SE's Beneish M-Score or its related term are showing as below:

ARGX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.71   Med: -1.64   Max: 8.34
Current: -1.02

During the past 13 years, the highest Beneish M-Score of argenx SE was 8.34. The lowest was -3.71. And the median was -1.64.


argenx SE Beneish M-Score Historical Data

The historical data trend for argenx SE's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Beneish M-Score Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 -3.71 8.34 4.71 -1.02

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.71 - - - -1.02

Competitive Comparison of argenx SE's Beneish M-Score

For the Biotechnology subindustry, argenx SE's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where argenx SE's Beneish M-Score falls into.



argenx SE Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of argenx SE for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6031+0.528 * 1.027+0.404 * 0.7948+0.892 * 2.9856+0.115 * 1.0417
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5057+4.679 * 0.022276-0.327 * 0.9716
=-0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $499 Mil.
Revenue was $1,226 Mil.
Gross Profit was $1,108 Mil.
Total Current Assets was $4,124 Mil.
Total Assets was $4,542 Mil.
Property, Plant and Equipment(Net PPE) was $23 Mil.
Depreciation, Depletion and Amortization(DDA) was $111 Mil.
Selling, General, & Admin. Expense(SGA) was $710 Mil.
Total Current Liabilities was $423 Mil.
Long-Term Debt & Capital Lease Obligation was $15 Mil.
Net Income was $-295 Mil.
Gross Profit was $24 Mil.
Cash Flow from Operations was $-420 Mil.
Total Receivables was $277 Mil.
Revenue was $411 Mil.
Gross Profit was $381 Mil.
Total Current Assets was $2,774 Mil.
Total Assets was $3,134 Mil.
Property, Plant and Equipment(Net PPE) was $16 Mil.
Depreciation, Depletion and Amortization(DDA) was $104 Mil.
Selling, General, & Admin. Expense(SGA) was $470 Mil.
Total Current Liabilities was $302 Mil.
Long-Term Debt & Capital Lease Obligation was $9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(499.271 / 1226.316) / (277.275 / 410.747)
=0.407131 / 0.675051
=0.6031

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(381.316 / 410.747) / (1108.481 / 1226.316)
=0.928348 / 0.903911
=1.027

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4123.737 + 22.676) / 4542.458) / (1 - (2774.197 + 16.235) / 3134.261)
=0.087187 / 0.1097
=0.7948

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1226.316 / 410.747
=2.9856

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(104.342 / (104.342 + 16.235)) / (111.307 / (111.307 + 22.676))
=0.865356 / 0.830755
=1.0417

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(709.539 / 1226.316) / (469.921 / 410.747)
=0.578594 / 1.144064
=0.5057

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((15.354 + 422.993) / 4542.458) / ((9.009 + 302.277) / 3134.261)
=0.0965 / 0.099317
=0.9716

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-295.053 - 24.084 - -420.327) / 4542.458
=0.022276

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

argenx SE has a M-score of -0.94 signals that the company is likely to be a manipulator.


argenx SE Beneish M-Score Related Terms

Thank you for viewing the detailed overview of argenx SE's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE (argenx SE) Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.